Biotech Bearish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Galena Biopharma (NASDAQ:GALE), Insmed Incorporated (NASDAQ:INSM), CytRx Corporation (NASDAQ:CYTR)

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm currently has a $6.00 price target on the stock. Maxim Group’s target price would suggest a potential upside of 62.16% from the stock’s previous close. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -7.30% … Continue reading Biotech Bearish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Galena Biopharma (NASDAQ:GALE), Insmed Incorporated (NASDAQ:INSM), CytRx Corporation (NASDAQ:CYTR)

Biotech Losers: ACADIA Pharmaceuticals (NASDAQ:ACAD), Incyte Corporation (NASDAQ:INCY), Galena Biopharma (NASDAQ:GALE), Alexion Pharmaceuticals (NASDAQ:ALXN)

Board of Directors of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) adopted an updated annual incentive cash compensation program for its executive officers to be effective beginning with 2014. The description of this program is set forth in Exhibit 99.1 and is incorporated herein by reference. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock performance was -6.80% in last session and finished the day at $24.27. Traded volume was 3.59million shares … Continue reading Biotech Losers: ACADIA Pharmaceuticals (NASDAQ:ACAD), Incyte Corporation (NASDAQ:INCY), Galena Biopharma (NASDAQ:GALE), Alexion Pharmaceuticals (NASDAQ:ALXN)

MannKind Corporation (NASDAQ:MNKD) on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 … Continue reading Biotech Most Volatile: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares climbed 4.96% to $3.60. The company on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was … Continue reading Biotech Gainers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN)

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. (NASDAQ:GALE) securities between November 6, 2013 and February 14, 2014. Galena Biopharma Inc. (NASDAQ:GALE) stock performance was -12.42% in last session and finished the day at $2.82. Traded volume was 17.65 million shares in … Continue reading Biotech Active Runners: Galena Biopharma Inc. (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals Inc. (NYSEMKT:INO)

Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) reported financial results for the fourth quarter and year ended December 31, 2013. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock performance was -2.29% in last session and finished the day at $3.42. Traded volume was 7.95 million shares in the last session and the average volume of the stock remained 8.89 million shares. The beta of the stock remained 3.55. Inovio Pharmaceuticals … Continue reading Healthcare Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Galena Biopharma (NASDAQ:GALE)